Mostrando 101 - 120 Resultados de 124 Para Buscar '"oratorio"', tiempo de consulta: 0.09s Limitar resultados
  1. 101
    Publicado 1994
    Materias:
    CD Audiom
  2. 102
  3. 103
    “…BACKGROUND: Ocrelizumab, an anti-CD20 humanized monoclonal antibody, reduced disease progression in pivotal trials of patients with relapsing (OPERA I, OPERA II) and primary progressive (ORATORIO) multiple sclerosis (MS). These effects may be particularly important among patients with increased disability. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  4. 104
    Tabla de Contenidos: “…Salve Rex Christe -- Psallite superi -- Qui non diligit te -- O Domine quia refugium -- Templa nunc fument -- Oratorio seu Dialogus poenitentis animae cum Deo -- Festis laeta sonent.…”
    CD Audiom
  5. 105
    Tabla de Contenidos: “…The Creatión-Oratorio for solo Voices, Chourus and orchestra.…”
    CD Audiom
  6. 106
    CD Audiom
  7. 107
    por Geminiani, Francesco, 1687-1762
    Publicado 1997
    CD Audiom
  8. 108
    CD Audiom
  9. 109
    CD Audiom
  10. 110
    CD Audiom
  11. 111
    por Stravinsky, Igor, 1882-1971
    Publicado 1993
    CD Audiom
  12. 112
    CD Audiom
  13. 113
  14. 114
    “…Large trials conducted for ocrelizumab showed malignancies in a total of 4 cases with RRMS in OPERA 1 trial conducted over 2 years from 2011 to 2013 (breast cancer, renal cell carcinoma, and melanomas) and in 11 cases with PPMS seen in ORATORIO trial conducted in 2017. There are currently no other published case reports of breast cancer in setting of ocrelizumab use for MS outside of large trials on literature review.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  15. 115
    “…BACKGROUND: Recently, ocrelizumab (Ocrevus®) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  16. 116
    por Abert, Hermann, 1871-1927
    Publicado 2007
    Tabla de Contenidos: “…Childhood -- Travels of the child prodigy -- Works from the grand tour -- Studies in Salzburg -- The first operas in Vienna -- Gesellschaftsmusik and church music of 1769 -- The first Italian journey -- The second and third Italian journeys -- Opera seria -- Early operas and the oratorio la betulia liberata -- Church and instrumental works, 1769-1773 -- On the road to 'La finta giardiniera' -- Opera buffa -- La finta giardiniera -- Mozart in Salzburg, 1775 -- Munich and Augsburg -- Mannheim -- Arrival in Paris : tragédie lyrique -- 'Opéra comique' -- The music dramas of Gluck -- Mozart in Paris -- Homecoming -- Service at the Salzburg court -- Sacred and instrumental works, 1779-1781-- König Thamos and Zaide -- Idomeneo -- First steps in Vienna -- The German singspiel -- Die Entführung aus dem Serail -- Engagement and marriage -- Mozart's personality -- Relations with Constanze, friends and colleagues, 1782-1786 -- Mozart and Freemasonry -- In the service of the aristocracy and society -- Plans for new operas -- Mozart and artistic creativity -- Perfpimd changes in style: the influence of J.S. …”
    Libro
  17. 117
    “…Real‐world effectiveness data for ocrelizumab were consistently favorable, with reductions in relapse rate and disease progression rates similar to those reported in the OPERA I/OPERA II and ORATORIO clinical trials, including in studies with more diverse patient populations not well represented in the pivotal trials. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  18. 118
    “…OBJECTIVE: To assess the efficacy of ocrelizumab compared with interferon beta-1a (IFNβ1a)/placebo on thalamic volume loss and the effect of switching to ocrelizumab on volume change in the Phase III trials in relapsing MS (RMS, OPERA I/II; NCT01247324/NCT01412333) and in primary progressive MS (PPMS, ORATORIO; NCT01194570). METHODS: Thalamic volume change was computed using paired Jacobian integration and analyzed using an adjusted mixed-effects repeated measurement model. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  19. 119
    “…In particular, OPERA I and II trials, which were performed in patients with RRMS, showed a reduction in the annualized relapse rate, the risk of disability progression, and the number of new/enlarging T2 lesions and enhancing lesions measured using brain magnetic resonance. The ORATORIO trial, performed in PP subjects, showed that OCR can reduce disability progression, improve performance on the timed 25-foot walk, and decrease the total volume of T2 lesions and the mean number of new or enlarging T2 lesions. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  20. 120
    “…The phase III trial (ORATORIO) in patients with PPMS met its primary efficacy endpoint: the percentage of patients with 12-week confirmed disability progression was significantly lower in the active treatment group (32.9%) than in patients receiving placebo (39.3%). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
Herramientas de búsqueda: RSS